Tue, February 11, 2025
[ Tue, Feb 11th 2025 ]: techUK
AI Action Summit: Day 4
Mon, February 10, 2025
Sun, February 9, 2025

Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say

Merck KGaA, a German science and technology company, is currently in discussions to acquire SpringWorks Therapeutics, a U.S.-based biotech firm, according to sources familiar with the matter. SpringWorks Therapeutics specializes in developing treatments for severe rare diseases and cancer, with its lead candidate, nirogacestat, recently receiving FDA approval for treating desmoid tumors. The potential acquisition could enhance Merck's portfolio in oncology and rare diseases, aligning with its strategic focus on expanding its healthcare business. However, details such as the deal's value and structure remain undisclosed, and there's no confirmation yet on whether an agreement will be reached.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/general/exclusive-germany-s-merck-kgaa-in-talks-to-buy-us-biotech-firm-springworks-sources-say/ar-AA1yLgI5 ]